Get ahead of the curve - 'Clinical Evidence 2030' ...

Representation of the vision for clinical evidence 2030.

The article titled "Clinical Evidence 2030" published in Clinical Pharmacology and Therapeutics (Jan 2025) discusses the vision for clinical evidence generation by 2030, emphasizing patient-centred approaches, efficient study designs, and the integration of real-world evidence (RWE).

Here at Dash Global we're already able to turn this vision into reality for clients in 2025.

We whole heartedly support its:

1. Patient-Centric Approach: The emphasis on placing patients at the centre of clinical evidence generation will fast become essential, as it ensures that healthcare decisions align with real-world needs.

2. Efficiency in Clinical Trials & RWE: The focus on bridging data gaps and making clinical trials more efficient and impactful is a positive step toward reducing the time and cost of bringing new treatments to market.

3. Transparency and Trust: The article’s call for transparency in evidence generation and evaluation is crucial for building trust among stakeholders, including patients, regulators, and healthcare providers.

If we do have critical comments they all relate to how you move from vision to reality. Over the past five years DaSH Global have been implementing the vision...

Critical challenges:

1. Implementation Challenges: While the article highlights the importance of patient involvement, it does not address the practical challenges of engaging diverse patient populations, especially in underrepresented communities.

   
   

   {Solution: DaSH Global's innovative partnership model provides a powerful solution. By collaborating with trusted organizations such as Lung Cancer Nursing UK and the Roy Castle Lung Cancer Foundation, we have established national networks dedicated to patient-centred care and engagement. Coupled with the advanced capabilities of ClinicalNet—a global clinical trial matching platform—we have created an unparalleled ability to connect with diverse groups who have traditionally been under-served. This approach ensures that every voice is heard and that healthcare advancements reflect the needs of all communities, paving the way for truly inclusive clinical evidence generation.}

   
   

2. Data Privacy Concerns: The vision for greater healthcare data access raises concerns about data privacy and security, which are not sufficiently explored in the article.

   
   

   {Solution: Here again, our long-standing social partnerships and technical expertise, honed over years of collaboration with national advocacy and patient support groups, have positioned us as a trusted broker in the digital healthcare landscape. By fostering meaningful connections and delivering innovative solutions, we ensure that patients and stakeholders alike can rely on us to bridge gaps and build trust in every interaction.}

   
   

3. Cost Implications: The proposed reforms, such as advanced analytics and innovative study designs, could significantly increase costs, potentially limiting accessibility for smaller organizations.

   
   

   {Solution: This is where our multi-client, strategic partnership truly delivers value. Rather than investing in entire departments filled with costly data and analytics specialists, you can adopt a smarter, scalable approach. Working with DaSH Global, start small, gain insight into this emerging arena, and tailor your investment to precisely match your needs. It's a streamlined way to not only save resources but also position yourself ahead of the competition with confidence and agility.}

For Clinical Evidence, let Dash Global be your strategic digital health partner, creating transparency, trust and the evidence you need to align stakeholders and speed winning therapies to market.

Author: Lee Wemyss, Co-founder DaSH Global Ltd. April 2025